Improved Outcome of Human Immunodeficiency Virus-Associated Plasmablastic Lymphoma of the Oral Cavity in the Era of Highly Active Antiretroviral Therapy: A Report of Two Cases

• Published in: Leukemia & lymphoma Vol. 45; no. 9; pp. 1881 - 1885
• Main Authors: Lester, Richard, Li, Charles H, Phillips, Peter, Shenkier, Tamara N, Gascoyne, Randy D, Galbraith, Paul F, Vickars, Linda M, Leitch, Heather A
• Format: Journal Article
• Language: English
• Published: United States Informa UK Ltd 01-09-2004; Taylor & Francis
• Subjects: Acquired Immunodeficiency Syndrome - complications; Acquired Immunodeficiency Syndrome - drug therapy; Acquired Immunodeficiency Syndrome - immunology; Acquired Immunodeficiency Syndrome - virology; Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; HAART; HIV; HIV - physiology; Human immunodeficiency virus; Humans; Lymphoma, Non-Hodgkin - complications; Lymphoma, Non-Hodgkin - drug therapy; Lymphoma, Non-Hodgkin - pathology; Male; Middle Aged; Mouth Neoplasms - complications; Mouth Neoplasms - drug therapy; Mouth Neoplasms - pathology; Plasmablastic lymphoma; Treatment Outcome
• ISSN: 1042-8194; 1029-2403
• DOI: 10.1080/10428190410001697395

Plasmablastic lymphoma (PBL) is a recently described type of non-Hodgkin's lymphoma (NHL) that occurs in up to 3% of patients with HIV infection. Although the clinical-pathological features of several patients with HIV-associated plasmablastic lymphoma are documented, detailed description of clinical outcome is limited to isolated case reports. Generally, the response to lymphoma therapy is poor and survival is short. Response to highly active anti-retroviral therapy (HAART), however, has also been described. In this report, we describe the clinical course of two patients diagnosed with HIV-associated PBL in the era of HAART. One patient had a complete response to HAART, with a response-duration of 14 months, followed by relapse in the gastrointestinal tract several months after an anti-retroviral holiday. He is currently in complete remission (CR) eight months from diagnosis of relapse after receiving a full course of combination chemotherapy with modified CHOP, and 25 months from initial diagnosis. A second patient responded to brief chemotherapy in conjunction with HAART and is in clinical CR ten months from diagnosis. These cases illustrate that immunologic and virologic control with HAART may be beneficial for treating PBL and may possibly maintain continued CR. We advocate a high index of suspicion for primary PBL or its recurrence in patients with HIV infection, a history of low CD4 counts or high viral load, and oral or gastrointestinal symptoms.